Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Withdrawn 1Recruiting 1Available 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Endocrine 8NET 3Sarcoma 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 378Carcinoid Tumor 40Gastro-enteropancreatic neuroendocrine tumor 36Pancreatic Neoplasms 27Carcinoma, Neuroendocrine 27Neoplasms 25Adenoma, Islet Cell 23Pheochromocytoma 17Paraganglioma 17Neoplasm Metastasis 17Stomach Neoplasms 15Neuroblastoma 14Gastrointestinal Neoplasms 14Carcinoma, Hepatocellular 12Thyroid Neoplasms 11Prostatic Neoplasms 11Breast Neoplasms 11Sarcoma 10Esophageal Neoplasms 10Colorectal Neoplasms 10Lung Neoplasms 9Rectal Neoplasms 8Gastrointestinal Stromal Tumors 8Cholangiocarcinoma 8Carcinoma, Medullary 8Carcinoma 8Brain Neoplasms 8Anus Neoplasms 8Liver Neoplasms 7Colonic Neoplasms 7

Interventions

pasireotide 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Hypoglycemia × NET × Clear all
NCT06881992 2026-05-18

Tumor HI

Rezolute

Phase 3 Recruiting
16 enrolled
EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT07262970 2025-12-04

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Rezolute

Available
EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡